SLAMF1

Across TCGA pan-cancer cohorts, SLAMF1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLAMF1 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLAMF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLAMF1 expression acts as an unfavorable survival marker.

STAD, READ, and SARC are the cancer types where SLAMF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.113	0.730	<.001	18	view →
READ	DFS	Median	III,IV	0.182	0.745	.007	12	view →
SARC	DFS	Median	All	0.155	0.614	.001	6	view →
LUSC	OS	Median	All	0.198	0.729	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.094	0.429	.016	6	view →
COAD	OS	Median	All	0.166	0.678	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLAMF1–STAD (OS)

Open the STAD breakdown →